Profile data is unavailable for this security.
About the company
InDex Pharmaceuticals Holding AB is a Sweden-based company, which is primarily engaged in the healthcare industry. The Company is focused in pharmaceuticals development. The Company's drug candidate is cobitolimod that helps in ulcerative colitis treatment. In addition, the Company develops a platform of patent protected substances, DNA based ImmunoModulatory Sequences (DIMS), that helps in the treatment of various immunological diseases. The Company also offers diagnostic kit DiBiCol, which is a PCR-based method that monitors seven biomarkers specific for ulcerative colitis or Crohn’s disease from a single colonic biopsy. InDex Pharmaceuticals Holding AB operates as a parent for InDex Pharmaceuticals AB and InDex Diagnostics AB. Among the Company's shareholders are SEB Venture Capital, Industrifonden and NeoMed Management.
- Revenue in SEK (TTM)108.34m
- Net income in SEK-56.48m
- Incorporated2016
- Employees7.00
- LocationInDex Pharmaceuticals Holding ABBerzelius Vag 13SOLNA 171 65SwedenSWE
- Phone+46 812203850
- Fax+46 850884739
- Websitehttps://www.indexpharma.com/